Author

F. Grosveld

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

C. Wang· 4 shared D. Drabek· 4 shared W. Li· 4 shared B. L. Haagmans· 3 shared F. J. M. van Kuppeveld· 3 shared R. van Haperen· 3 shared B. J. Bosch· 2 shared B.-J. Bosch· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

C. Wang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants

W. Du, D. L. Hurdiss, D. Drabek, A. Z. Mykytyn, F. Kaiser, M. Gonzalez-Hernandez, D. Munoz-Santos, M. M. Lamers, R. van Haperen, W. Li, I. Drulyte, C. Wang, I. Sola, F. Armando, G. Beythien, , B. J. Bosch

bioRxiv · Feb 17, 2022 · PreprintMicrobiology

Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein

C. Wang, R. van Haperen, J. Gutierrez-Alvarez, W. Li, N. Okba, I. Albulescu, I. Widjaja, B. van Dieren, R. Fernandez-Delgado, I. Sola, D. Hurdiss, O. Daramola, F. Grosveld, F. van Kuppeveld, B. Haagmans, , B.-J. Bosch

This study isolates two cross-reactive monoclonal antibodies against multiple Betacoronaviruses, identifying a conserved vulnerable site on the spike protein.

bioRxiv · Oct 20, 2020 · PreprintMicrobiology

SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model

B. L. Haagmans, D. Noack, N. M. A. Okba, W. LI, C. Wang, T. Bestebroer, R. de Vries, S. Herfst, D. de Meulder, P. van Run, M. M. Lamers, B. Rijnders, C. Rokx, F. J. M. van Kuppeveld, F. Grosveld, , B. Rockx

This study shows that high-dose convalescent plasma or monoclonal antibodies protect hamsters from SARS-CoV-2-induced lower respiratory disease, but lower doses are ineffective.

bioRxiv · Aug 24, 2020Microbiology

A human monoclonal 1 antibody blocking SARS-CoV-2 infection

C. Wang, W. Li, D. Drabek, N. M. A. Okba, R. van Haperen, A. D. M. E. Osterhaus, F. J. M. van Kuppeveld, B. L. Haagmans, F. Grosveld, B.-J. Bosch

This paper reports a human monoclonal antibody that neutralizes SARS-CoV-2 and SARS-CoV, targeting a shared epitope for potential prevention and treatment of COVID-19.

bioRxiv · Mar 11, 2020Microbiology